Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells.

By K. Le Blanc, I. Rasmusson, B. Sundberg, C. Götherström, Moustapha Hassan, M. Uzunel, O. Ringdén. The Lancet, 2004

2,696 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Clinical Trials with Mesenchymal Stem Cells: An Update (2016, background): “One-year follow-up observations reported a remarkable clinical response and no complications (68).”
Mechanisms involved in the therapeutic properties of mesenchymal stem cells. (2009, background): “have shown that MSC infusions are effective in treating cases of severe, steroid-refractory Graft versus Host Disease (GvHD) in humans [75].”
Immunobiology of mesenchymal stem cells (2013, background): “One of the early clinical studies of MSCs is to treat GvHD patients.(85) However, the therapeutic effects are not always achieved.”
Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages (2009, background): “In many phase I and II clinical studies MSCs, autologous or allogeneic, have been shown to be potentially efficacious for treatment of a wide variety of clinical conditions such as acute graft versus host disease after allogeneic hematopoietic stem cell transplantation [40,41], myocardial, infarctio”